Could slightly elevated blood sugar levels lead to serious health problems in the future? A single patient's question sparked ...
“We know from data that primary care, which sees over 90% of patients with type 2 diabetes, that there’s not much uptake or ...
News-Medical.Net on MSN
How early diabetes management influences long-term outcomes
Could slightly elevated blood sugar levels lead to serious health problems in the future? A single patient's question sparked ...
2don MSN
Evolutionary comparison points to pigs as superior models for human pancreas and diabetes research
Pancreas development in pigs resembles humans much more closely than does the established mouse model. An international team ...
BOSTON — Health care professionals should use a broad range of tools to diagnose diabetic peripheral neuropathy, and ...
Travel Noire on MSN
Wheels Up, Insulin Packed: How To Travel Boldly With Diabetes
Since her 2021 diabetes diagnosis, Stephanie Guignard, a nurse practitioner, has made it her mission to educate people on how ...
9hon MSN
Novo touts blood sugar control and cardiovascular benefits of Wegovy pill with new trial data
Novo Nordisk (NVO) posts new late-stage trial data to highlight blood sugar control and cardiovascular benefits associated with its Wegovy in a pill. Read more here.
Verywell Health on MSN
We Asked a Doctor If You Should Track Your Blood Sugar Even If You Don't Have Diabetes
There is limited research on the clinical benefit of continuous glucose monitors (CGMs) in healthy individuals, but anecdotal ...
Danielle Bittterman on finding vulnerabilities in LLMs to make them safer, in this edition of the AI Prognosis newsletter.
Novo Nordisk made a surprise bid for Metsera to boost its weight-loss market lead, trading at just 12x 2026 EPS. Read why NVO stock is a buy.
Tidepool today announced a strategic collaboration with Oura to support a groundbreaking dataset for diabetes research.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback